THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

THERMO FISHER SCIENTIFIC INC. : Regulation FD Disclosure (form 8-K)

01/21/2022 | 06:33am EDT

Item 7.01 Regulation FD Disclosure.

On January 21, 2022, Thermo Fisher Scientific Inc. (the "Company") notified the holders of its $350,000,000 aggregate principal amount of 3.650% Senior Notes due 2025 (the "Notes") that it will redeem all of the Notes on February 7, 2022 (the "Redemption Date"). The Notes will be redeemed at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of the Notes to be redeemed discounted to the Redemption Date on a semi-annual basis at a comparable treasury rate plus 25 basis points, plus accrued and unpaid interest on the Notes to be redeemed, if any, to, but excluding, the Redemption Date.

The Company intends to fund the aggregate redemption price using cash on hand.

The information in Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the Company's statements about its intended source of funds for the redemption. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to general economic conditions and related uncertainties; the effect of changes in governmental regulations; and any natural disaster, public health crisis or other catastrophic event. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are on file with the SEC and available in the "Investors" section of the Company's website under the heading "SEC Filings," and other documents the Company files with the SEC. While the Company may elect to update forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this Current Report on Form 8-K.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about THERMO FISHER SCIENTIFIC
05/11TRANSCRIPT : Thermo Fisher Scientific Inc. Presents at Bank of America 2022 Healthcare Con..
CI
05/11IonPath, Inc. announced that it has received funding from Thermo Fisher Scientific Inc.
CI
05/10Thermo Fisher Scientific Introduces QualTrak Biopharma qPCR Solutions to Streamline Bio..
CI
05/06THERMO FISHER SCIENTIFIC INC. Management's Discussion and Analysis of Financial Condit..
AQ
05/06Thermo Fisher Scientific to Present at BofA Securities 2022 Healthcare Conference
BU
05/06INSIDER SELL : Thermo Fisher Scientific
MT
05/05Interim report 1 January – 31 March 2022
AQ
05/04Thermo Fisher Scientific Inc. Launches Thermo Scientificdionex CR-CTC III Application W..
CI
04/29Morgan Stanley Adjusts Thermo Fisher Scientific's Price Target to $670 from $700, Keeps..
MT
04/28SECTOR UPDATE : Health Care Stocks Carried Higher in Thursday Markets Recovery
MT
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 42 581 M - -
Net income 2022 6 865 M - -
Net Debt 2022 25 677 M - -
P/E ratio 2022 31,3x
Yield 2022 0,22%
Capitalization 212 B 212 B -
EV / Sales 2022 5,58x
EV / Sales 2023 5,28x
Nbr of Employees 130 000
Free-Float 88,9%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | TMO | US8835561023 | MarketScreener
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 541,42 $
Average target price 669,21 $
Spread / Average Target 23,6%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
THERMO FISHER SCIENTIFIC-18.86%211 945
DANAHER CORPORATION-24.26%178 394
INTUITIVE SURGICAL, INC.-37.74%80 295
SIEMENS HEALTHINEERS AG-17.38%63 485
EDWARDS LIFESCIENCES CORPORATION-24.70%60 652
BOSTON SCIENTIFIC CORPORATION-6.64%56 697